外周血中肿瘤相关生物标志物预测非小细胞肺癌免疫治疗疗效的研究进展
摘要
疗的出现改变了非小细胞肺癌的治疗策略 , 然而并非所有患者都可以从中获益。外周血检测作为临床常规的检
查方案 , 具有简便且创伤小的优势 , 且能在不同时间点多点取样以达到纵向对比分析并全程监测的目的。本文
主要针对外周血晚期非小细胞肺癌免疫治疗疗效相关生物标志物现状及进展进行概括总结。
关键词
全文:
PDF参考
[1]Zhang Q, Luo J, Wu S, Si H, Gao C, Xu W,
Abdullah SE, Higgs BW, Dennis PA, van der Heijden MS,
Segal NH, Chaft JE, Hembrough T, Barrett JC, Hellmann
MD. Prognostic and Predictive Impact of Circulating
Tumor DNA in Patients with Advanced Cancers Treated
with Immune Checkpoint Blockade. Cancer Discov. 2020
Dec;10(12):1842-1853. doi: 10.1158/2159-8290.CD-
20-0047. Epub 2020 Aug 14. PMID: 32816849; PMCID:
PMC8358981.
[2]Hellmann MD, Nabet BY, Rizvi H, Chaudhuri
AA, Wells DK, Dunphy MPS, Chabon JJ, Liu CL, Hui
AB, Arbour KC, Luo J, Preeshagul IR, Moding EJ,
Almanza D, Bonilla RF, Sauter JL, Choi H, Tenet M,
Abu-Akeel M, Plodkowski AJ, Perez Johnston R, Yoo
CH, Ko RB, Stehr H, Gojenola L, Wakelee HA, Padda
SK, Neal JW, Chaft JE, Kris MG, Rudin CM, Merghoub T,
Li BT, Alizadeh AA, Diehn M. Circulating Tumor DNA
Analysis to Assess Risk of Progression after Long-term
Response to PD-(L)1 Blockade in NSCLC. Clin Cancer
Res. 2020 Jun 15;26(12):2849-2858. doi: 10.1158/1078-
0432.CCR-19-3418. Epub 2020 Feb 11. PMID:
32046999; PMCID: PMC7299781.
[3]Chen G, Huang AC, Zhang W, Zhang G, Wu
M, Xu W, Yu Z, Yang J, Wang B, Sun H, Xia H, Man
Q, Zhong W, Antelo LF, Wu B, Xiong X, Liu X, Guan
L, Li T, Liu S, Yang R, Lu Y, Dong L, McGettigan S,
Somasundaram R, Radhakrishnan R, Mills G, Lu Y, Kim
J, Chen YH, Dong H, Zhao Y, Karakousis GC, Mitchell
TC, Schuchter LM, Herlyn M, Wherry EJ, Xu X, Guo
W. Exosomal PD-L1 contributes to immunosuppression
and is associated with anti-PD-1 response. Nature. 2018
Aug;560(7718):382-386. doi: 10.1038/s41586-018-
0392-8. Epub 2018 Aug 8. PMID: 30089911; PMCID:
PMC6095740.
[4]Yang Q, Chen M, Gu J, Niu K, Zhao X, Zheng
L, Xu Z, Yu Y, Li F, Meng L, Chen Z, Zhuo W, Zhang
L, Sun J. Novel Biomarkers of Dynamic Blood PD-L1
Expression for Immune Checkpoint Inhibitors in Advanced
Non-Small-Cell Lung Cancer Patients. Front Immunol.
2021 Apr 16;12:665133. doi: 10.3389/fimmu.2021.665133.
PMID: 33936103; PMCID: PMC8085403.
[5]Li C, Li C, Zhi C, Liang W, Wang X, Chen X,
Lv T, Shen Q, Song Y, Lin D, Liu H. Clinical significance
of PD-L1 expression in serum-derived exosomes in
NSCLC patients. J Transl Med. 2019 Oct 29;17(1):355.
doi: 10.1186/s12967-019-2101-2. PMID: 31665020;
PMCID: PMC6820965.
[6]Chmielewska I, Grenda A, Krawczyk P, Frąk
M, Kuźnar Kamińska B, Mitura W, Milanowski
J. The influence of plasma sPD-L1 concentration
on the effectiveness of immunotherapy in advanced
NSCLC patients. Cancer Immunol Immunother. 2023
Dec;72(12):4169-4177. doi: 10.1007/s00262-023-
03552-x. Epub 2023 Oct 10. PMID: 37816808; PMCID:
PMC10700455.
[7]Costantini A, Julie C, Dumenil C, HéliasRodzewicz Z, Tisserand J, Dumoulin J, Giraud V, Labrune
S, Chinet T, Emile JF, Giroux Leprieur E. Predictive role
of plasmatic biomarkers in advanced non-small cell lung
cancer treated by nivolumab. Oncoimmunology. 2018 Apr
20;7(8):e1452581. doi: 10.1080/2162402X.2018.1452581.
PMID: 30221046; PMCID: PMC6136870.
[8]Guibert N, Delaunay M, Lusque A, Boubekeur
N, Rouquette I, Clermont E, Mourlanette J, Gouin S,
Dormoy I, Favre G, Mazieres J, Pradines A. PD-L1
expression in circulating tumor cells of advanced nonsmall cell lung cancer patients treated with nivolumab.
Lung Cancer. 2018 Jun;120:108-112. doi: 10.1016/
j.lungcan.2018.04.001. Epub 2018 Apr 3. PMID:
29748004.
[9]Zhou YJ, Li G, Wang J, Liu M, Wang Z, Song
Y, Zhang X, Wang X. PD-L1: expression regulation.
Blood Sci. 2023 Jan 13;5(2):77-91. doi: 10.1097/
BS9.0000000000000149. PMID: 37228770; PMCID:
PMC10205351.
[10]Li W, Wu F, Zhao S, Shi P, Wang S, Cui D.
Correlation between PD-1/PD-L1 expression and
polarization in tumor-associated macrophages: A key player
in tumor immunotherapy. Cytokine Growth Factor Rev.
2022 Oct;67:49-57. doi: 10.1016/j.cytogfr.2022.07.004.
Epub 2022 Jul 18. PMID: 35871139.
(25 摘要 Views, 52 PDF Downloads)
Refbacks
- 当前没有refback。